How the f can the s and p only be down 1% or so yet the stocks are like they were on Liberation day? Thats some AI driven manipulation probably. How can you crash 98% of stocks and still only have 401ks down about 1-2%? Was their question probably.

---

F in the chat 

---

How the f did reddit crush earnings and is still dipping after rising high? Nothing happened.

---

Copy pasta if you want it The Trump administration is negotiating a deal with weight-loss drugmakers Eli Lilly and Novo Nordisk that would allow the lowest doses of some of their obesity drugs to be sold to consumers at $149 for a month's supply via TrumpRx, according to people familiar with the matter. The deals would also result in Medicare and Medicaid covering the drugs for weight-loss, the people said, which would be a boon to the companies. The discussions are still ongoing but if agreements are finalized, Trump is expected to announce them Thursday morning at the White House, alongside pharmaceutical executives, the people said. The agreement would allow Medicaid coverage for the popular but pricey drugs known as GLP-1s, including bestsellers Wegovy and Zepbound, to treat obesity. And it would require Medicare to cover the drugs for obese people who are also at high risk of other health problems, the people familiar with the matter said. The lowest dose of Novo Nordisk's Wegovy would be offered through TrumpRx at $149, the people said. The starting dose of Lilly's Zepbound would be sold for $299, $50 less than the price that the company currently charges patients buying directly through Lilly's direct-to-consumer website online, according to one of the people. In addition, Lilly would sell the starting dose of its weight-loss pill, orforglipron, for $149 via TrumpRx, if the drug, which is now in testing, is approved by the Food and Drug Administration. Ozempic, the diabetes drug also made by Novo Nordisk that is already covered for many Medicare and Medicaid patients, may also be offered on TrumpRx, according to one of the people, who didn't specify a potential price. As part of the deal negotiations, Lilly is seeking a voucher from the FDA that would speed up review of the company's weight-loss pill, the people said. The company has applied for the voucher, but it wasn't clear if it will be awarded by Thursday. The voucher could potentially be very helpful for Lilly, allowing it to speed up FDA review of its application to just one to two months. Normally, the FDA takes anywhere from 6 to 10 months from accepting a new drug application to complete its review. The potential agreements involve promises by the drugmakers to provide patients with "digital solutions" meant to encourage diet and exercise, people familiar said. Currently, Medicare drug-benefit plans are permitted to cover the weight-loss drugs for nonobesity uses, such as reducing risk of heart attacks or sleep apnea. Few states cover the drugs for weight loss in their Medicaid programs. A spokeswoman for Lilly said the company "is in discussions with the administration to further expand patient access, preserve innovation, and promote affordability of our medicines. We do not have specific details to share at this time." A spokeswoman for Novo Nordisk said the company "is engaged in constructive discussions with the Administration" and wants to make its drugs more affordable. A CMS spokesperson said the president wants to make these products more affordable, and that when a deal is completed, the administration will announce it. Trade publication Endpoints News earlier reported a deal was near. The deal is part of the negotiations the Trump administration kicked off with major drugmakers in July in an attempt to lower U.S. drug costs with a policy known as "most favored nation" pricing. So far Pfizer, AstraZeneca and EMD Serono have announced deals with the administration. Health Secretary Robert F. Kennedy Jr. has made fighting obesity and accompanying chronic diseases one of the primary goals of his Make America Healthy Again agenda. But in the past he has expressed skepticism about GLP-1s and last year criticized legislation to broaden coverage of the drugs, which he said would cost about $3 trillion. Centers for Medicare and Medicaid Services Administrator Mehmet Oz, a heart surgeon, persuaded Kennedy to back the coverage expansion by showing him scientific studies about how the medicines can prevent heart disease and diabetes, and data on the resulting cost savings to the federal government, people familiar with the matter said. President Trump last month said the "fat loss drug," or Novo Nordisk's Ozempic, could be sold to Americans at $150 or "much lower," but Oz quickly stepped in front of him and said the negotiations were still ongoing. Write to Liz Essley Whyte at liz.whyte@wsj.com and Peter Loftus at Peter.Loftus@wsj.com

---

Moved to a 70-30 income, mostly mid length t-bonds last month because this shit is so stupid. If the market dumps im up 10% to and can buy the bottom market down ~ -25% nice 40% burger or so. if it dosent I'll miss out on 30% or so and will have to take my 7-10% penance in not trusting 30-50 f/pe.

---

is down 1%, not 10…da f

---

The F I just bought HOOD calls at close and it dips another 1.5% AH LMAO

---

AMD theta f*cking everyone!

---

F@g

---

F

---